男子不妊症に対する経口男性ホルモン剤Mesteroloneの効果について

Abstract

Oral administration of androgen has not been used extensively due to the weak androgenic and spermatogenic action as well as to side effect to the liver function. Recently, 1α-methy1-5α-androstane-17β-ol-3-one was developed. This androgen is said to be effective upon oral administration. The drug was administered to 40 men with oligospermia to study if there is any suppressive action on gonadotropin. Administration of 30mg a day, total of 900~6, OOOmg increased the concentration of spermatozoa in 60 %, and the rate of motility and number of motile spermatozoa in 47.5 % and 50 % respectively. Pregnancy developed in 4 cases. Findings suggestive of central inhibiting action of this drug were observed in 7. In 5 cases, azoospermia appeared after administration of 1, 900~6, 800mg, while a decrease in number of motile spermatozoa was seen in 2 cases given 900 and 4900 mg respectively. Immediately after the discontinuation of the drug or during the marked decrease of motile spermatozoa, the urinary gonadotropin decreased remarkably. These findings suggest some central inhibiting action by this drug. In these cases with decrease of spermatozoa, increase was again noted after discontinuation of the drug for 2 to 5 months. Application of rebound phenomenon might make this drug even more useful.